Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.
Trial Details
- NCT ID
- NCT05338931
- Phase
- PHASE1 / PHASE2
- Sponsor
- AbClon
- Status
- RECRUITING
- Cancer Type
- T-Cell Lymphoma Lymphoma
- Interventions
- AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
- Locations (sample)
- Seoul, South Korea|37.566,126.9784
Key Eligibility Criteria
- B cell non-Hodgkin lymphoma based on WHO classification 2017
- incompatible with existing standard therapies or have had disease progression, and whose standard therapies do not currently have available standar…
- The Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
- adequate hematological, kidney, liver, lung, heart and bone marrow function without blood transfusion within two weeks prior to screening
For full eligibility, visit ClinicalTrials.gov.